

**COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

NOTE: This special called meeting will be held virtually via Zoom webinar.

Thursday, May 18, 2023
1:00 P.M. to 4:00 P.M. (Eastern)

Access Information

Smartphone/Web	Dial-In
https://magellanhealth.zoom.us/j/93321225965 Webinar ID: 933 2122 5965 Password: 239251	+1 312 626 6799 (US Toll) OR +1 646 558 8656 (US Toll) Webinar ID: 933 2122 5965 Password: 239251

AGENDA

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
 - a. Approval of November 2022 Meeting Minutes
 - b. Approval of March 2023 Meeting Minutes
- IV. New Business**
 - a. New Products to Market to be reviewed as single products:
 - i. Auvelity™ (Antidepressants: Other)
- V. New Therapeutic Class with Criteria Review**
 - a. Sickle Cell Anemia Treatments
 - i. Endari™
 - ii. Oxbryta®
- VI. Therapeutic Classes with Recommended Changes**
 - a. Narcotics: Short-Acting
 - b. Erythropoiesis Stimulating Proteins
 - c. Glucagon Agents
 - d. Diabetes: DPP-4 Inhibitors
 - e. Diabetes: Insulins and Related Agents
 - f. Uterine Disorder Treatments
- VII. Consent Agenda**
 - a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<ul style="list-style-type: none"> • Analgesics, Narcotics Long-Acting Opioids • Analgesics, Narcotics Short-Acting (Narcotics: Agonist/Antagonists) • Analgesics, Narcotics (Narcotics: Fentanyl Buccal Products) • Androgenic Agents • Antihyperuricemics • Antimigraine Agents – Other (Antimigraine Agents - CGRP Inhibitors) • Antimigraine Agents – Triptans • (Antimigraine Agents - 5-HT1Receptor Agonists) • Bone Resorption Suppression & Related • Colony Stimulating Factors • Glucocorticoids, Oral • Growth Hormone • Hypoglycemics, AlphaglucoSIDase Inhibitors (Diabetes: AlphaGlucoSIDase Inhibitors) 	<ul style="list-style-type: none"> • Hypoglycemics, Meglitinides (Diabetes: Meglitinides) • Hypoglycemics, Metformins (Diabetes: Metformins) • Hypoglycemics, SGLT2 Inhibitors (Diabetes: SGLT2 Inhibitors) • Hypoglycemics, Sulfonylureas (Diabetes: Sulfonylureas) • Hypoglycemics, Thiazolidinediones (TZD) (Diabetes: Thiazolidinediones) • Neuropathic Pain • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) • Opiate Dependence Treatments • Pancreatic Enzymes • Phosphate Binders • Progestins for Cachexia • Skeletal Muscle Relaxants • Thrombopoiesis Stimulating Proteins (Thrombopoiesis Stimulating Agents)
---	--

VIII. Informational

- a. Weight Management Agents

IX. Adjournment

- a. Schedule of Upcoming Meetings
 - i. **July 20, 2023**
 - ii. **September 21, 2023**
 - iii. **November 16, 2023**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria please go to <https://kyportal.magellanmedicaid.com/provider/public/home.xhtml>.

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at: <https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.